Danish
English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Højdepunkter fra den 15. årlige kongres for EAHAD
Endelig analyse fra det pivotale fase 3 HOPE-B genterapiforsøg: Stabil steady-state effektivitet og sikkerhed af Etranacogene Dezaparvovec hos voksne med svær eller moderat svær hæmofili B
Wolfgang Miesbach1; Frank WGLeebeek2; Michael Recht3; Nigel S. Key4; Susan Lattimore3; Giancarlo Castaman5; Michiel Coppens6; David Cooper7; Sergio Slawka7; Stephanie Verweij7; Robert Gut7; Ricardo Dolmetsch7; Yanyan Li8; Paul E. Monahan8; Steven W. Pipe9
HOPE-B efterforskere1; Universitetshospital Frankfurt, Frankfurt am Main, Tyskland2; Erasmus MC, University Medical Center Rotterdam, Holland3; Oregon Health & Science University, Portland, OR, USA4; University of North Carolina, Chapel Hill, NC, USA5; Center for blødningsforstyrrelser og koagulation, Careggi Universitetshospital, Firenze, Italien6; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Holland7; uniQureBV, Amsterdam, Holland/uniQure Inc. Lexington, MA, USA8; CSL Behring, King of Prussia, PA, USA9; University of Michigan, Ann Arbor, MI, USA
RETTET INDHOLD
